Related Experiment Video
Updated: Jun 20, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Cucurbitacin B inhibits STAT3 and the Raf/MEK/ERK pathway in leukemia cell line K562
Kin Tak Chan1, Kwan Li, Shiu Lam Liu
1Department of Technology and Product Development, CK Life Sciences Int'l., (Holdings) Inc., 2 Dai Fu Street, Tai Po Industrial Estate, Hong Kong SAR, China.
Abstract:
Cucurbitacin B is a natural anti-cancer compound found in Cucurbitaceae. Although the anti-cancer activity of cucurbitacin B in human leukemia cells has been reported, the underlining mechanism is still unclear. To clarify its anti-cancer activity and the mechanism of action, five different leukemia cell lines (CCRF-CEM, K562, MOLT-4, RPMI-8226 and SR) of the National Cancer Institute panel were treated with cucurbitacin B. Leukemia cell growth was inhibited by cucurbitacin B with GI(50) ranged from 15.6 nM to 35.3 nM and the growth inhibition effect was attributable to G2/M phase arrest and apoptosis. Western blotting analysis of cell signaling molecules indicated that cucurbitacin B inhibits STAT3 activation and the Raf/MEK/ERK pathway in the K562 cells.
Related Concept Videos
Inhibition of Cdk Activity
Inhibition of CDK Activity
MAPK Signaling Cascades
Abnormal Proliferation
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle